Clinical trials: Pharmakokinetic, active
Pharmakokinetic, Open Label
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants
TNX-102 SL has recently been approved by the United States (US) Food and Drug Administration (FDA) under the brand name TONMYA for the treatment of fibromyalgia.
- Conditions
- Pharmakokinetic, Open Label, Phase 1
- Trial name
- NCT07413367
- Testing
- TNX-102 SL Tablet
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tonix Pharmaceuticals, Inc.
Stoma Ileostomy, Ileostomy - Stoma
Impact on the Absorption of Drugs in Ostomy Patients
Peroral administration is the preferred way of taking medication. However, the special absorption conditions in ostomy patients are generally not addressed in approval studies and there is also little other literature on this…
- Conditions
- Stoma Ileostomy, Ileostomy - Stoma, Colostomy - Stoma, Absorption
- Trial name
- STAR (NCT07138326)
- Testing
- Monitoring
- Where
- Austria
- Volunteers
- 128 people
- Sponsor
- WiGeV Klinik Ottakring
Sickle Cell Disease (SCD)
Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia
The goal of this study is to evaluate if patients with sickle cell disease can achieve a maximum tolerate dose of hydroxuyrea (HU) over a period of 12 months faster with pharmacokinetic testing than the standard of care bloodwork…
- Trial name
- OPTIMA (NCT06761560)
- Testing
- Pharmacokinetic based dosage change, Pharmacokinetic dosing
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- Yves Pastore